News Could UK's post-Brexit regulator evaluate value as well? But longer-term benefits could include faster reimbursement decisions.
News Hunt under pressure over plans to quit EMA Britain could be in "second rank" of medicines access, warn MPs.
News EU drug regulators concerned about Brexit impact European regulators concerned over impact of EMA move.
Views & Analysis Fast-track appraisals and Managed Access Agreements Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.
Views & Analysis High-value, high-cost drugs: how to pay for them Experts call for urgent development of new drug funding mechanisms.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
